118 related articles for article (PubMed ID: 3436616)
1. Effect of fenfluramine on growth hormone and prolactin secretion in obese subjects.
Altomonte L; Zoli A; Alessi F; Ghirlanda G; Manna R; Greco AV
Horm Res; 1987; 27(4):190-4. PubMed ID: 3436616
[TBL] [Abstract][Full Text] [Related]
2. Effect of fenfluramine on insulin/growth hormone ratio in obese subjects.
Altomonte L; Zoli A; Ghirlanda G; Manna R; Greco AV
Pharmacology; 1988; 36(2):106-11. PubMed ID: 3281173
[TBL] [Abstract][Full Text] [Related]
3. Effect of fenfluramine on prolactin secretion in obese patients: evidence for serotoninergic regulation of prolactin in man.
Barbieri C; Magnoni V; Rauhe WG; Zanasi S; Caldara R; Ferrari C
Clin Endocrinol (Oxf); 1983 Dec; 19(6):705-10. PubMed ID: 6360431
[TBL] [Abstract][Full Text] [Related]
4. Depending on the stimulus, central serotoninergic activation by fenfluramine blocks or does not alter growth hormone secretion in man.
Casanueva FF; Villanueva L; Peñalva A; Cabezas-Cerrato J
Neuroendocrinology; 1984 Apr; 38(4):302-8. PubMed ID: 6374488
[TBL] [Abstract][Full Text] [Related]
5. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.
Cordido F; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483
[TBL] [Abstract][Full Text] [Related]
6. Effect of fenfluramine on prolactin and thyroid-stimulating-hormone response to thyrotropin-releasing-hormone in obese and normal women.
Argenio G; Bernini G; Vivaldi MS; Del Corso C; Monzani F; Baschieri L; Bertolozzi G; Santoni R; Franchi F; Luisi M
Eur J Clin Pharmacol; 1990; 39(1):13-6. PubMed ID: 2125937
[TBL] [Abstract][Full Text] [Related]
7. Specific stimulation of brain serotonin mediated neurotransmission by dexfenfluramine does not restore growth hormone responsiveness in obese women.
Kars ME; Pijl H; Cohen AF; Frölich M; Schoemaker HC; Brandenburg HC; Meinders AE
Clin Endocrinol (Oxf); 1996 May; 44(5):541-6. PubMed ID: 8762730
[TBL] [Abstract][Full Text] [Related]
8. Effects of fenfluramine and ritanserin on prolactin response to insulin-induced hypoglycemia in obese patients: evidence for failure of the serotoninergic system.
Bernini GP; Argenio GF; Vivaldi MS; Del Corso C; Sgrò M; Franchi F; Luisi M
Horm Res; 1989; 31(3):133-7. PubMed ID: 2501208
[TBL] [Abstract][Full Text] [Related]
9. Prolactin and growth hormone secretion in chemically induced and genetically obese mice.
Sinha YN; Salocks CB; Vanderlaan WP
Endocrinology; 1975 Dec; 97(6):1386-93. PubMed ID: 1107014
[TBL] [Abstract][Full Text] [Related]
10. The effect of hypocaloric diet with and without D-fenfluramine treatment on growth hormone release after growth hormone-releasing factor stimulation in patients with android obesity.
Medeiros-Neto G; Lima N; Perozim L; Pedrinola F; Wajchenberg BL
Metabolism; 1994 Aug; 43(8):969-73. PubMed ID: 8052154
[TBL] [Abstract][Full Text] [Related]
11. Effects of naloxone on prolactin, growth hormone and cortisol response to insulin hypoglycemia in obese subjects.
Papalia D; Lunetta M; Di Mauro M
J Endocrinol Invest; 1989 Dec; 12(11):777-82. PubMed ID: 2693516
[TBL] [Abstract][Full Text] [Related]
12. Naloxone does not modify fenfluramine-induced prolactin increase in obese patients.
Argenio GF; Bernini GP; Vivaldi MS; del Corso C; Santoni R; Franchi F
Clin Endocrinol (Oxf); 1991 Dec; 35(6):505-8. PubMed ID: 1769132
[TBL] [Abstract][Full Text] [Related]
13. Acute and chronic estrogen effects upon serum somatomedin activity, growth hormone, and prolactin in man.
Wiedemann E; Schwartz E; Frantz AG
J Clin Endocrinol Metab; 1976 May; 42(5):942-52. PubMed ID: 178687
[TBL] [Abstract][Full Text] [Related]
14. Serotonergic regulation of prolactin and growth hormone secretion in man.
Lewis DA; Sherman BM
Acta Endocrinol (Copenh); 1985 Oct; 110(2):152-7. PubMed ID: 4060968
[TBL] [Abstract][Full Text] [Related]
15. Role of the serotonin receptor subtype 5-HT1D on basal and stimulated growth hormone secretion.
Mota A; Bento A; Peñalva A; Pombo M; Dieguez C
J Clin Endocrinol Metab; 1995 Jun; 80(6):1973-7. PubMed ID: 7775648
[TBL] [Abstract][Full Text] [Related]
16. Attenuated pulse size, disorderly growth hormone and prolactin secretion with preserved nyctohemeral rhythm distinguish irradiated from surgically treated acromegaly patients.
van der Klaauw AA; Pereira AM; van Thiel SW; Frolich M; Iranmanesh A; Veldhuis JD; Roelfsema F; Romijn JA
Clin Endocrinol (Oxf); 2007 Apr; 66(4):489-98. PubMed ID: 17371464
[TBL] [Abstract][Full Text] [Related]
17. Impaired prolactin secretion in obese patients.
Cavagnini F; Maraschini C; Pinto M; Dubini A; Polli EE
J Endocrinol Invest; 1981; 4(2):149-53. PubMed ID: 6792262
[TBL] [Abstract][Full Text] [Related]
18. In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.
Maccario M; Procopio M; Grottoli S; Oleandri SE; Razzore P; Camanni F; Ghigo E
J Clin Endocrinol Metab; 1995 Dec; 80(12):3774-8. PubMed ID: 8530634
[TBL] [Abstract][Full Text] [Related]
19. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
Lee EJ; Nam SY; Kim KR; Lee HC; Cho JH; Nam MS; Song YD; Lim SK; Huh KB
J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
[TBL] [Abstract][Full Text] [Related]
20. The effect of acetylsalicylic acid and diclofenac on stimulated growth hormone and prolactin secretion in humans.
Caviezel F; Cattaneo AG; Tell A; Corino T; Mascherpa M
Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):502-4. PubMed ID: 6642786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
